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Background: Azithromycin mass distribution was given to residents of Gurage zone Cheha district in 2004, 2005
and 2006 for three consecutive years with more than 90% coverage. The effect of treatment in the study
community was not yet determined. The present study was therefore designed to assess the effect of azithromycin
on the prevalence of active trachoma two years after three rounds of mass treatment of the community at Cheha
district, Gurage zone.
Methods: A multistage stratified cluster random survey was employed to determine the prevalence of active
trachoma among children aged 1 to 9. Selected children were examined for trachoma using the simplified WHO
grading system and their households were assessed for trachoma risk factors.
Results: This survey demonstrated that the prevalence of active trachoma in the study community was 22.8%
(95% CI 18.24% - 27.36%) that was lower than that of Southern Nations, Nationalities, and People's Regional
prevalence (33.2%) in 2006. Only 27.6% (95% CI 25.7% - 30.1%) of the study population had a safe and clean water
supply, whereas 42.7% (95% CI 39.8% - 46.2%) of the visited households had simple pit latrines.
Conclusion: This survey demonstrated that despite repeated mass oral azithromycin distributions, the prevalence of
active trachoma was still high. Therefore, the other components of the SAFE strategy such as fly control program,
improving the water sources, measures to improve face washing and construction of utilizable latrines that are
being implemented through the health extension package have to be integrated with mass azithromycin treatment
to eliminate active trachoma in the district.
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Trachoma is a chronic infectious keratoconjunctivitis
caused by serotypes A, B, Ba and C of the bacterium Chla-
mydia trachomatis [1,2]. It is the world’s leading cause of
preventable blindness [3]. Sixty three million people suffer
from active trachoma infection, 7.6 million have trachoma-
tous trichiasis and nearly 10 million people are visually im-
paired or irreversibly blind as a result of trachoma [3]. The
burden of this disease falls disproportionately on poor rural
communities, predominantly in Sub-Saharan Africa [4].* Correspondence: amarebem6@gmail.com
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reproduction in any medium, provided the orWorld Health Organization (WHO) called to eliminate
blinding trachoma by the year 2020 through SAFE strat-
egy [5]. SAFE strategy is a comprehensive public health
approach which combines treatment, Surgery (to correct
advanced stages of the disease) and Antibiotics (azithro-
mycin to treat infection in individuals), with prevention,
Facial cleanliness (to reduce transmission of trachoma)
and Environmental improvement (through increased ac-
cess to clean water and improved sanitation) [6]. Previ-
ous studies have shown that in the short term, mass
antibiotic distribution can dramatically decrease the
prevalence of ocular strains of Chlamydia in villages.
Current WHO guidelines recommend 3 annual mass
distributions [7].al Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Gurage zone Cheha district for three consecutive years
through the ORBIS international program in collaboration
with the zonal health bureau. First round was distributed
from December 1–10, 2004 with 90% coverage, second
round from December 1–10, 2005 with 92% coverage and
third round from December 1–10, 2006 with 93% coverage.
Baseline estimates and projections of active trachoma for
the districts before azithromycin distribution was greater
than 40% [unpublished observation]. As part of SAFE strat-
egy implementation, each Kebeles (the lowest political ad-
ministrative unit in Ethiopia) of the district have trained
health extension worker who screen community members
for active trachoma and trichiasis, and refer them to the
nearby health centers. They also educate the community
on personal hygiene, latrine construction and utilization,
and proper animal waste disposal. There are also billboards
posted by government and non government organization
that provide information on mode of transmission, preven-
tion and treatment of trachoma in local language.
Though different studies have shown that community-
wide treatment with oral azithromycin markedly reduces
C. trachomatis infection and clinical trachoma in en-
demic areas [8,9], the effect of treatment in the study
community is not yet determined.
Therefore this research was conducted with a general
objective of assessing the effect of azithromycin mass
treatment on the prevalence of active trachoma two
years after three rounds of mass treatment of the com-
munity at Cheha district, Gurage zone that will help for
evidence based planning in the future.
Methods
Study design and setting
A community-based cross sectional survey was con-
ducted Cheha district found in Gurage zone, in Southern
Nations, Nationalities and People Region of Ethiopia 185
Kms south west of Addis Ababa from September 1, 2008
to September 30, 2008. This district consisted of 42
kebeles with a total population of 175,597, projected for
the year 2008 out of which children aged 1 to 9 years
accounted for 56,194 [10]. The main sources of income
are subsistence agriculture and trade. The major part of
the district (71%) has a middle land climatic condition,
20% High land and the rest 9% low land with the alti-
tude range of 1200 m to 2600 m and annual rainfall ran-
ging from 800 – 1200 mm [10]. The district has one
hospital, four health centers, one health station and 37
health posts that makes 62% physical health service
coverage in the year 2007. There are two ophthalmic
nurses and four integrated eye care workers who give
eye care services at the district. All of the 83 health ex-
tension workers in the district were trained by ORBIS
on SAFE strategy and help the community on trachomaspecific control interventions such as fly control pro-
gram, building and utilization of latrine and measures to
improve face washing.
Sample size and sampling procedure
The sample size of the study population, children aged 1 to
9 years who resided in the study district, was estimated by
using single population proportion formula, [n = (Z α/2)2 /
p (1-p)] [11]. The following assumptions were made: 95%
confidence, 5% margin of error, design effect of 2, and
62.6% prevalence rate from previous studies [12]. Comput-
ing with the above formula and 10% of contingency gives a
total sample size of 792. The required number of clusters
was determined by dividing the calculated sample size by
the cluster size (60 children in one cluster) resulting in 13
clusters. After calculating the sampling interval, the 13 clus-
ters were selected from 10 kebeles of the district. In each
selected cluster, compact segment sampling method was
employed to collect the data.
Data collection
A pre-tested and structured questionnaire was used to
guide for the systematic data collection process and find-
ings were recorded on the forms. Clinical evaluation for
trachoma follicles (TF) (defined as the presence of five or
more follicles in the upper tarsal conjunctiva) was used to
evaluate the response of active trachoma to azithromycin
[13]. All selected children were assessed for active trachoma
by the principal investigator who had 3 years of experience
in trachoma grading using WHO trachoma simplified grad-
ing system with binocular examination loupe (2.5 times
magnification) and torch light [14]. The children were also
assessed for facial uncleanness that was defined by the pres-
ence of ocular discharge, nasal discharge and/or flies on the
face. Backyards were visited for availability of waste disposal
and latrine, and their utilization by the household members.
Ethical considerations
The study protocol was approved by the Research Ethics
Committee of the department of ophthalmology of both
University of Gondar and Addis Ababa University. A
support letter from the zonal and district health offices
was obtained. The purpose of the study was explained
and verbal consent from their parents (care takers) was
obtained. All children and parents (care takers) who
were diagnosed to have active trachoma were given
tetracycline ointment to be applied twice daily for six
weeks and those with trichiasis and other ocular prob-
lems were referred to respective health institution for
management.
Data analysis
Data were entered and analyzed using SPSS version 15
statistical package (SPSS, Inc., Chicago, IL, USA). The
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Statistical significance was determined by P-value < 0.05.
Results
A total of 768 children aged 1 to 9 years (with a 97%
coverage of the sample size) that included 386 (50.3%)
males and 382 (49.7%) females participated in the sur-
vey. The mean age of the study group was 6.79 years
(Table 1). Out of the 768 children included in the study,
93 (12.1%) didn’t receive azithromycin in the past;
whereas 86 (11.2%) had received only once, 86 (11.2%)
had received twice and 503 (65.5%) received three times.
In this study, we found a total of 175 (22.8%) (95% CI
18.24% - 27.36%) children had active trachoma with a
slight male preponderance; that is 96 (54.9%) were
males. The highest of prevalence trachoma was in the
age group 2 to 6 years (Figure 1). Two hundred and sev-
enty six children (35.9%) were having unclean face with
flies around their faces and eyes, eye and nasal discharge
at the time of the survey. Out of the 49 children who
had never received azithromycin in the past, 12 (24.5%)
had active trachoma while 28 (47.5%) of children who
received the drug one time, 54 (51.4%) of children who
received the drug two times and 81 (14.6%) of children
who received the drug three times had active trachoma
(Figure 2). Three hundred sixteen (41.1%) of the children
were found out to have scared tarsal conjunctiva.
Out of the visited ten Kebeles only three had a im-
proved water sources (tape water and protected wells)Table 1 Socio-demographic and environmental variables, and
1–9 years at Gurage zone Cheha district in October 2008, n =
Variable
Yes n (%)
Sex Male 93 (12.1)
Female 82 (10.7)
Total 175 (22.8)
Age 1 3 (0.4)
2 6 (0.8)
3 18 (2.35)
4 24 (3.1)
5 37 (4.85)
6 39 (5.1)
7 25 (3.2)
8 14 (1.8)
9 9 (1.2)
Total 175 (22.8)
Past Azithromycin treatment Never 53 (6.9)
Once 57 (7.4)
Two times 42 (5.5)
Three Times 23 (3.0)
Total 175 (22.8)that accounted for 212 [27.6% (95% CI 25.7% - 30.1%)]
of the study population. The rest of the district people
used rivers, streams and well as source of water without
any treatment. Three hundred and twenty eight [42.7%
(95% CI 39.8% - 46.2%)] of the visited households had
simple pit latrines, that were made by lying two logs of
wood over a pit with wide gap in between the logs and
almost all did not have lid to cover, whereas the rest of
the population used open fields. It was observed that
none of the visited households had proper solid waste
and animal disposal. Almost all disposed animal waste in
their back yards where they have false banana plantation.
Discussions
Although active trachoma have not been eliminated
from this district after three rounds of community-wide
treatment with oral azithromycin, the finding of this sur-
vey demonstrated that the overall prevalence of active
trachoma in the study area was lower than that of
Southern Nations, Nationalities, and People's Regional
prevalence ( 33.2%) in 2006 [12]. In line with this, stud-
ies from different parts of the country reported that
mass treatments with oral azithromycin markedly reduce
C. trachomatis infection and clinical trachoma in en-
demic areas [14,15]. In spite of the fact that the preva-
lence of active trachoma was decreasing in the area,
active trachoma is still a disease of public health interest.
Despite the efforts of community health extension
workers and other nongovernmental organization toazithromycin treatment history of children aged
768
Active trachoma (TF) Chi square test
No n (%) Total n (%)
298 (38.8) 391 (50.9) P = 0.502
295 (38.4) 377 (49.1)
593 (77.2) 768 (100)
16 (2.1) 19 (2.5) P = 0.002
19 (2.50) 25 (3.3)
18 (2.35) 36 (4.7)
8 (1.0) 32 (4.1)
11 (1.45) 48 (6.3)
70 (9.1) 109 (14.2)
131 (17.1) 156 (20.3)
194 (25.2) 208 (27.0)
126 (16.4) 135 (17.6)
593 (77.2) 768 (100)
40 (5.2) 93 (12.1) P = 0.001
29 (3.8) 86 (11.2)
44 (5.7) 86 (11.2)
480 (62.5) 503 (65.5)
593 (77.2) 768 (100)
Figure 1 Prevalence of active trachoma by age and sex in children aged 1–9 years at Gurage zone Cheha District in October 2008.
Admassu et al. BMC Pediatrics 2013, 13:199 Page 4 of 5
http://www.biomedcentral.com/1471-2431/13/199implement the SAFE strategy in the community, the preva-
lence of active trachoma is still very high. A possible ex-
planation for this might be that there is no adequate water
supply in the major part of the community. Furthermore,
47.8% of the community lacks functional latrine and almost
all the community dispose animal waste product open field.
Another possible explanation might be that mass azithro-
mycin treatment may not be integrated with health promo-
tion through health education on primary eye care,
personal and environmental hygiene of the Districts. Recent
evidence suggests that all the A, F, E components of the
SAFE strategy have independent protective effects against
active trachoma [16].
The chance of getting active trachoma was lower for
children who had received azithromycin three times
than twice or once (odds ratio of 3.2, 2.0 and 1.2, re-
spectively). This finding, supported by many other re-
ports [14,17-21], emphasizes that repeated doses of
azithromycin are important for reduction and elimin-
ation of the infection.
The current study found that the prevalence of active
trachoma is highest in the age range of 3 to 6 years. TheFigure 2 Prevalence of active trachoma by frequency of azithromycin
Cheha District in October 2008.higher prevalence of trachoma among these age groups
may be explained by the fact that young children are
dependent on their families for their personal hygiene.
Spending several hours playing on the ground (exposing
them to dirt that attracts flies to them) could also put
them at risk.
The SAFE strategy anticipates the use of antibiotics
and surgery only as short-term interventions that are de-
livered through the health services. Azithromycin is ex-
pensive but easily administrable, safe and effective drug
for treatment of trachoma; however, if nothing else in
the community is changed, the disease can return even-
tually to its previous levels. Hence, health promotion
and environmental improvements have pivotal role as a
consolidating long-term interventions for marked reduc-
tion in active disease, which is thought to be an indica-
tor for future blindness.
Limitations of the study
In this study, the prevalence of active trachoma was de-
termined by clinical finding not on microbiological iden-
tification of Chlamydia trachomatis. But some studiestreatment history in children aged 1–9 years at Gurage zone
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evaluate the response of azithromycin to active trachoma
cases in a country with limited resources9. Though ef-
forts were made to get accurate data, there could be a
recall bias by parents as to how many times their chil-
dren received azithromycin treatment in the past. Base-
line data on the prevalence of active trachoma was not
determined based on the WHO recommended trachoma
survey methods, hence we used national survey result
for comparison of our data.
Conclusion
Though it was demonstrated that repeated mass oral azi-
thromycin distributions has reduced active trachoma in the
community, the prevalence of active trachoma in the dis-
trict was not negligible; therefore, other trachoma specific
control interventions such as fly control program, water
supply changes, measures to improve face washing and
construction of utilizable latrines that are being imple-
mented by the health extension package has to be strength-
ened in the district. This essentially needs intersectoral
collaboration between governmental organizations like the
district health bureau and other bureau such as water de-
velopment bureau, environmental protection/sanitation
bureau and education bureau - strongly arguing for contin-
ued use of all the components of the SAFE strategy to-
gether in the community. Finally, as the current prevalence
of TF was still more than 10%, we recommend azithromy-
cin mass distribution in the community.
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